Concepedia

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Megan H. Pollack, Helen Clare Dearden, K. Rapazzo, Ian Valentine, Andrew S. Brohl, Kristin Kathleen Ancell, Georgina V. Long, Alexander M. Menzies, Zeynep Eroglu, Douglas B. Johnson,

Annals of Oncology · 2017 · 392 citations · 14 references

DOIFull text

Open access

Concepts

References

14

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

, , +17

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

, , +17

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

, , +17

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. Johnson, Justin M. Balko, Margaret Compton et al. · New England Journal of Medicine · 2016 · 2.3K citations · Full text

, , +17